WO2007034748A1 - 腸管免疫調節剤 - Google Patents
腸管免疫調節剤 Download PDFInfo
- Publication number
- WO2007034748A1 WO2007034748A1 PCT/JP2006/318390 JP2006318390W WO2007034748A1 WO 2007034748 A1 WO2007034748 A1 WO 2007034748A1 JP 2006318390 W JP2006318390 W JP 2006318390W WO 2007034748 A1 WO2007034748 A1 WO 2007034748A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclic tetrasaccharide
- intestinal
- intestinal immunity
- iga
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to an intestinal immunity regulator, and more particularly to an intestinal immunity regulator comprising a cyclic tetrasaccharide.
- IgA immunoglobulin A
- an object of the present invention is to provide an intestinal immunity regulator that can be continuously ingested in daily eating habits and is free from side effects.
- cyclic tetrasaccharide promotes the production of Ig A in the intestine by ingestion.
- the effect is exerted through Peyer's patch cells, the intestinal immune system.
- cyclic tetrasaccharides are IFNs that induce interleukin-4 (IL-4) production in Peyer's patch cells. Since it induces the production of ⁇ , it has been clarified that it has an action to suppress allergies.
- IL-4 interleukin-4
- the present invention solves the above problems by providing an intestinal immunity regulator comprising a cyclic tetrasaccharide as an active ingredient.
- the present invention since intestinal immunity can be easily adjusted, it is effective in preventing infections, allergies and the like.
- the intestinal immunity regulator of the present invention is used in daily eating habits.
- the cyclic tetrasaccharide as an active ingredient of the intestinal tract immunomodulator of the present invention is cyclo ( ⁇ 6) - ⁇ -D-darcopyranosyl mono (1 ⁇ 3) -a-D-darcopyranosyl mono (1 ⁇ 6)- a—D glucopyranosyl (1 ⁇ 3) a D darcoviranosyl (1 ⁇ non-reducing saccharide.
- This saccharide is produced by the method disclosed in International Publication No. WO02Z10361, etc.
- the starch power can also be produced by an enzymatic method, and the shape can be appropriately selected from syrup, honey-containing crystal powder, hydrated crystal, anhydrous crystal, amorphous solid, etc.
- the amount of cyclic tetrasaccharide in the intestinal immunity regulator is usually 1 to 100 wZw%, preferably 10 in terms of anhydride, as long as the intestinal immunity is exerted by ingesting in animals including humans. To 100 wZw%, more preferably 20 to lOOw Zw%.
- cyclic tetrasaccharide promotes the production of IFN- ⁇ without promoting the production of IL-4 against Peyer's patch cells, thereby making Th balance dominant and suppressing allergies. Furthermore, since cyclic tetrasaccharide is metabolized by lactic acid bacteria in the intestine and becomes an energy source thereof, it has an action of increasing the number of lactic acid bacteria and an action of activating lactic acid bacteria. Therefore, effective It is considered that the intestinal immunity regulator of the present invention containing a cyclic tetrasaccharide as a component improves the intestinal environment and normally regulates intestinal immunity.
- the mucosal immunomodulator of the present invention may be a cyclic tetrasaccharide alone, but includes a cyclic tetrasaccharide as an active ingredient, food and drink, pharmaceuticals, quasi drugs, health foods, feeds, feeds, etc.
- the composition in the form of Compositions include components that are acceptable in the above forms, such as water, alcohol, starch, protein, dietary fiber, carbohydrates, lipids, vitamins, minerals, flavorings, coloring agents, sweeteners, seasonings, spices, Stabilizers, antioxidants, preservatives, etc. can be added.
- proteins such as ratatopherin, casein, collagen, soybean protein or their degradation products, flavonoids such as rutin, hesperidin, quercetin, isoflavone or glycosides thereof, calcium salts such as calcium lactate and calcium glycephosphate, vitamin A , Vitamin Bl, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E and other vitamins or their derivatives, maltose, trehalose, maleretinoretrehalose, ratatosucrose, -gerose, isomaretorose, -gerooligosaccharide Sugars such as isomaltoligosaccharides and cyclodextrins; amino sugars such as dalcosamine, galactosamine and mannosamine; darcosaminoglycans such as hyaluronic acid, chondroitin sulfate and heparan sulfate; Sugar alcohols such as bitol and maltitol
- the intestinal immunity regulator of the present invention regulates intestinal immunity, viruses such as hepatitis A virus, poliovirus, rotavirus, cholera, shigella, typhoid, salmonella, and campyropac Bacteria such as turkey, rhinomycota, Vibrio parahaemolyticus, Brucella, E. coli O-157 It is used for the prevention or treatment of diseases caused by parasites such as nematodes, Shigella amoeba, cryptosporidium, malaria, microfilariae, or allergies such as food allergies and hay fever.
- viruses such as hepatitis A virus, poliovirus, rotavirus, cholera, shigella, typhoid, salmonella, and campyropac Bacteria such as turkey, rhinomycota, Vibrio parahaemolyticus, Brucella, E. coli O-157 It is used for the prevention or treatment of diseases caused by parasites such as nematodes, Shi
- a method for administering or ingesting the intestinal immunity regulator of the present invention may be administered or ingested within the range of 0.001 to 5 gZkg body weight, preferably 0.01 to 2 gZkg body weight, more preferably 0.1 to 2 gZkg body weight per day by the oral or tube route. 0. If it is less than OOlgZkg body weight, the desired effect is not exerted, and if it exceeds 5g Zkg body weight, it is difficult to take quantitatively and diarrhea may occur, which is not preferable.
- mice In order to examine the immunomodulatory action of various carbohydrates, the amount of IgA in the feces of mice fed with carbohydrates was measured.
- Six-week-old female BALBZc mice were preliminarily raised for one week in AIN-93G, a standard refined diet (for breeding) for nutritional studies using mice and rats published in 1993 by the National Nutrition Laboratory.
- mice were fed a standard purified feed (AIN-93G) containing no test carbohydrate. After 1 week, 2 weeks, 3 weeks, and 4 weeks after starting free consumption of the test diet or control diet, fresh feces were collected from the mouse, and the amount of IgA was measured using an ELIS A method using an anti-IgA antibody. (Mouse IgA ELIS A Quantitation Kit, manufactured by BETHYL). The average value of 5 mice was determined and the results are shown in Table 1. The percentage values in the table indicate the relative values for each week.
- mice reared with the control refined diet decreased the amount of IgA in the feces as the breeding period (weeks) progressed.
- This phenomenon is thought to be due to a decrease in the intestinal immunity function as a result of a decrease in the amount of antigens taken orally because the mice were bred with clean purified feed.
- cyclic tetrasaccharide further increases IgA in mouse feces and maintains IgA secretion at a high level even if kept on clean purified feed It was found to have an effect.
- the amount of IgA the amount of antibody per gram of content was measured by the ELIS A method using an anti-IgA antibody, and for the amount of IgG, the ELIS A method using an anti-IgG antibody (mouse IgG ELISA Quantitation Kit, manufactured by BETHYL). .
- the results are shown in Table 2.
- the culture supernatant is collected from each well, and the amount of IgA, TGF- ⁇ or IL 6 contained therein is determined by ELISA using anti-mouse IgA antibody, anti-mouse IL 6 antibody or anti-mouse TGF- ⁇ 1 antibody. Measurements were made and the average of 5 animals was determined. The results are shown in Table 3. The numerical values in the table indicate relative values (percentage) with respect to the amount of IgA, IL 6 or TGF- ⁇ produced in Peyer's patch cells collected from control mice.
- cyclic tetrasaccharide increased IgA secretion in Peyer's patch cells.
- the amount of cytoplasmic ins that stimulates the production of IgA such as IL 6 and TGF-j8 was also increased. From this result, it was found that cyclic tetrasaccharide has an action of promoting the secretion of IgA to Peyer's patch cells.
- the test carbohydrate increases lactic acid! It was found to have an effect of increasing lactic acid bacteria.
- the cyclic tetrasaccharide showed an effect of increasing the total amount of organic acids by increasing butyric acid, succinic acid, formic acid, and malic acid, which increase the amount of lactic acid.
- IFN — ⁇ and IL — produced by adding various carbohydrates to Peyer's patch cells collected from mouse force.
- Four quantities were measured.
- Six weeks old female BALB / c mice were fed standard purified diet ( ⁇ -93G) and pre-bred for one week, then Peyer's patch cells were collected according to the method of Experiment 3 and RPMI1640 containing 10% FCS and 10 mM HEPES.
- the cell concentration was adjusted to 1 ⁇ 10 6 cells / ml in the culture medium, and 1 ml was seeded per well in a 24-well microphone mouthplate. 0.
- a syrup-like cyclic tetrasaccharide was produced according to the method described in International Publication WO02Z10361.
- potato starch was made into about 6% starch milk, and calcium carbonate was added to this so that the concentration was 0.1%, adjusted to pH 6.0, and ⁇ -amylase (trade name “Terminal Mill” was added.
- the filtrate obtained is decolorized with activated carbon and purified by desalting with H-type and OH-type ion-exchanged resin. Further, it was concentrated to obtain a syrup-like intestinal immunity-modulating agent containing a cyclic tetrasaccharide having a concentration of 60%.
- This product contains 0.9% glucose, 1.5% isomaltose, 11.3% maltose, 60.1% cyclic tetrasaccharide, and 26.2% other carbohydrates per solid matter. It can be used as an intestinal immunity regulator of the present invention.
- the cyclic tetrasaccharide-containing syrup obtained by the method of Example 1 was replaced with a strongly acidic cation exchange resin (trade name “Amberlite CR-1310 (Na type)”, Organo Corporation. Column fractionation using a company).
- the resin was packed into four jacketed stainless steel columns with an inner diameter of 5.4 cm and connected in series to make the total length of the resin layer 20 cm. While maintaining the temperature in the column at 60 ° C, add 5vZv% of the sugar solution to the fat, and then fractionate by flowing 60 ° C warm water with SVO.13.
- the fraction containing a high content of cyclic tetrasaccharide is collected and concentrated to a concentration of about 85%. Then, the fraction is concentrated in an auxiliary crystal machine, stirred and slowly cooled, and the cyclic tetrasaccharide 5 containing water-containing crystals is about 2 % Was added and gradually cooled, taken out into a plastic vat, allowed to stand at room temperature for 2 days, and crystallized and matured to prepare a block. Next, this block was pulverized with a cutting machine to obtain a powdery crystalline intestinal immunity regulator containing cyclic tetrasaccharide.
- This product is a high-purity cyclic tetrasaccharide pentahydrate crystal having a purity per solid of 98% or more, and can be used as an intestinal immunity regulator of the present invention.
- a chewing gum was obtained by adding parts by mass and further mixing an appropriate amount of fragrance and colorant, followed by kneading with a roll and molding according to a conventional method.
- This product has good flavor and can regulate intestinal immunity when taken orally, so it is useful as a health food to maintain and enhance health.
- this product is dissolved in an appropriate amount of water and taken orally, it is possible to provide nutrition for patients who cannot take a normal meal, and the intestinal immunity function is regulated, so that a good recovery of the patient can be expected.
- Glucose-transferred hesperidin (trade name “Hi-G Hesperidin”)
- Syrup-shaped intestinal immunity regulator containing cyclic tetrasaccharide obtained in Example 1 2 parts by weight
- This product has a good flavor and, when taken orally, regulates intestinal immunity, so it is useful as a health food to maintain and improve health.
- the intestinal immunity regulator of the present invention has no side effects. Since it regulates intestinal immunity by daily intake, it prevents or infects such as food poisoning and allergies. Can be treated. It also increases the number of useful intestinal bacteria such as lactic acid bacteria and improves the intestinal environment, making it suitable for maintaining and improving health.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/067,577 US7973021B2 (en) | 2005-09-22 | 2006-09-15 | Immunomodulating agent in gut |
| GB0807337A GB2445891B (en) | 2005-09-22 | 2006-09-15 | Immunomodulating agent in gut |
| JP2007536470A JPWO2007034748A1 (ja) | 2005-09-22 | 2006-09-15 | 腸管免疫調節剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005275360 | 2005-09-22 | ||
| JP2005-275360 | 2005-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2007034748A1 true WO2007034748A1 (ja) | 2007-03-29 |
Family
ID=37888793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2006/318390 Ceased WO2007034748A1 (ja) | 2005-09-22 | 2006-09-15 | 腸管免疫調節剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7973021B2 (ja) |
| JP (1) | JPWO2007034748A1 (ja) |
| GB (1) | GB2445891B (ja) |
| WO (1) | WO2007034748A1 (ja) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05178876A (ja) * | 1991-12-27 | 1993-07-20 | Mochida Pharmaceut Co Ltd | 抗炎症・抗アレルギー作用を有するオリゴ糖誘導体 |
| JP2000060541A (ja) * | 1998-08-27 | 2000-02-29 | Fuyuki Mitsuyama | ビフィズス菌増殖促進物質と整腸物質とビフィズス菌製剤 |
| WO2001090338A1 (fr) * | 2000-05-22 | 2001-11-29 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | $g(a)-isomaltosyltransferase, procede de production et utilisation |
| WO2002010361A1 (en) * | 2000-08-01 | 2002-02-07 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | α-ISOMALTOSYLGLUCOSACCHARIDE SYNTHASE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF |
| JP2003522784A (ja) * | 2000-02-17 | 2003-07-29 | ワイス | プレバイオティック物質を含有する栄養配合物 |
| WO2004020552A1 (ja) * | 2002-08-30 | 2004-03-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | ラジカル反応抑制剤及びラジカル反応抑制方法並びにその用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5178876A (ja) * | 1974-12-28 | 1976-07-09 | Ayano Itsushiki | Nunonizuanotsusazunisashuosuruhoho |
| DE29911152U1 (de) | 1999-06-26 | 1999-11-04 | Mate Precision Tooling GmbH, 61440 Oberursel | Werkzeugvorrichtung zur spanenden Bearbeitung tafelförmiger Werkstücke |
| US20030003132A1 (en) | 2000-11-07 | 2003-01-02 | Norie Arai | Mucosal immunomodulator and use thereof |
| JP2002325555A (ja) | 2001-04-27 | 2002-11-12 | Takeda Food Products Ltd | 栄養障害による免疫機能低下を抑制する飲食品 |
| EP1616873B1 (en) * | 2003-04-03 | 2008-08-20 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Lipid-regulating agent and use thereof |
-
2006
- 2006-09-15 US US12/067,577 patent/US7973021B2/en not_active Expired - Fee Related
- 2006-09-15 JP JP2007536470A patent/JPWO2007034748A1/ja not_active Withdrawn
- 2006-09-15 WO PCT/JP2006/318390 patent/WO2007034748A1/ja not_active Ceased
- 2006-09-15 GB GB0807337A patent/GB2445891B/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05178876A (ja) * | 1991-12-27 | 1993-07-20 | Mochida Pharmaceut Co Ltd | 抗炎症・抗アレルギー作用を有するオリゴ糖誘導体 |
| JP2000060541A (ja) * | 1998-08-27 | 2000-02-29 | Fuyuki Mitsuyama | ビフィズス菌増殖促進物質と整腸物質とビフィズス菌製剤 |
| JP2003522784A (ja) * | 2000-02-17 | 2003-07-29 | ワイス | プレバイオティック物質を含有する栄養配合物 |
| WO2001090338A1 (fr) * | 2000-05-22 | 2001-11-29 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | $g(a)-isomaltosyltransferase, procede de production et utilisation |
| WO2002010361A1 (en) * | 2000-08-01 | 2002-02-07 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | α-ISOMALTOSYLGLUCOSACCHARIDE SYNTHASE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF |
| WO2004020552A1 (ja) * | 2002-08-30 | 2004-03-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | ラジカル反応抑制剤及びラジカル反応抑制方法並びにその用途 |
Non-Patent Citations (1)
| Title |
|---|
| TANIGUCHI H.: "Rinsho Eiyo Update Hojo Shokuhin to Eiyo Ryoho Kinosei Origoto", MEDICINA, vol. 39, no. 2, 10 February 2002 (2002-02-10), pages 275 - 277, XP003010850 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0807337D0 (en) | 2008-05-28 |
| JPWO2007034748A1 (ja) | 2009-03-26 |
| GB2445891A (en) | 2008-07-23 |
| US20100143389A1 (en) | 2010-06-10 |
| GB2445891B (en) | 2010-11-10 |
| US7973021B2 (en) | 2011-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1465505B1 (en) | Stimulation of the immune system with polydextrose | |
| KR102303570B1 (ko) | 에너지 소비의 촉진 및/또는 에너지 소비 기능 저하의 치료 및/또는 예방제, 또는 방법 | |
| CN104012838A (zh) | 非变应原性的成分和食品 | |
| JP5191955B2 (ja) | 粘膜免疫調節剤並びにその用途 | |
| EP0382355A2 (en) | Growth promoting agent for bacteria containing pullulan and/or dextran | |
| JP6742981B2 (ja) | 免疫調節剤及びその用途 | |
| CN118805891B (zh) | 一种抑制脂肪吸收、控制体重的组合物及其制备方法 | |
| JP3433917B2 (ja) | 体タンパク質蓄積効率を亢進する栄養組成物 | |
| KR101356330B1 (ko) | 간기능 개선제 | |
| JP5394644B2 (ja) | アスペルロシドまたはその類縁体を含む筋肉増強剤 | |
| JP5289952B2 (ja) | 免疫調節剤 | |
| WO2007034748A1 (ja) | 腸管免疫調節剤 | |
| JP2023154540A (ja) | 加齢性難聴の予防又は改善のための組成物 | |
| JP2008195713A (ja) | 免疫調節剤 | |
| EP2027862B1 (en) | Composition for enhancing immune function comprising zinc and a nigerooligosaccharide | |
| JP2005126429A (ja) | 免疫賦活剤、食品及び液状食品組成物 | |
| WO2021149224A1 (ja) | 骨代謝改善用組成物 | |
| CN114304611B (zh) | 水溶性复合营养素及其生产方法 | |
| JP6560471B1 (ja) | 骨形成促進剤、並びにこれを用いた骨代謝疾患の予防および/または治療剤 | |
| JP5107545B2 (ja) | パイエル板形成誘導組成物 | |
| JP4049278B2 (ja) | 腸内代謝改善剤 | |
| RU2802815C2 (ru) | Композиция, содержащая маннозный олигосахарид, способ её получения и применения | |
| JP2004059504A (ja) | 哺乳類に於けるサイトカイン類の産生異常を抑制及び/又は予防するための組成物 | |
| JPH10158173A (ja) | カルシウム吸収促進剤 | |
| JP5097935B2 (ja) | 哺乳類に於けるサイトカイン類の産生異常を抑制及び/又は予防するための組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| ENP | Entry into the national phase |
Ref document number: 2007536470 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12067577 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 0807337 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20060915 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 0807337.1 Country of ref document: GB Ref document number: 807337 Country of ref document: GB |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06798053 Country of ref document: EP Kind code of ref document: A1 |